John A. Taylor

Also affiliated with Baylor College of Medicine, The University of Kansas Cancer Center, University of Kansas Medical Center

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 8 papers. Top paper: “Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes”.

Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes

Nature Reviews Urology(2020)10.1038/s41585-020-0304-1

N/A

0.794DataRank · unranked

198 citations

Hikmat Al‐Ahmadie, Bishoy M. Faltas, John A. Taylor, Thomas W. Flaig, David J. DeGraff +5 more

Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex

Cell Death and Disease(2021)10.1038/s41419-021-03836-z

N/A

0.633DataRank · unranked

14 citations

Prasad Dandawate, David Standing, Sangita Bhattacharyya, Prabhu Ramamoorthy, Parthasarathy Rangarajan +13 more

IV vitamin C with chemotherapy for cisplatin ineligible bladder cancer patients (CI-MIBC) first-stage analysis NCT04046094.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e16540

N/A

0DataRank · unranked

2 citations

John A. Taylor, Qi Chen, Benjamin L. Woolbright, Ping Chen, Elizabeth Wulff‐Burchfield +4 more

The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with pan-Hsp90 Inhibition

Journal of Medicinal Chemistry(2021)10.1021/acs.jmedchem.0c01700

N/A

0DataRank · unranked

76 citations

Weiya Liu, Kristin Beebe, Monimoy Banerjee, Caitlin N. Kent, Vitumbiko Munthali +6 more

Understanding the microbiome as a mediator of bladder cancer progression and therapeutic response

Urologic Oncology Seminars and Original Investigations(2024)10.1016/j.urolonc.2024.07.004

N/A

0DataRank · unranked

2 citations

John A. Taylor, Benjamin L. Woolbright, Mahgol Golshani

4-Methylpyrazole-mediated inhibition of cytochrome P450 2E1 protects renal epithelial cells, but not bladder cancer cells, from cisplatin toxicity

Toxicological Sciences(2025)10.1093/toxsci/kfaf053

N/A

0DataRank · unranked

3 citations

Erika Abbott, Benjamin L. Woolbright, Anup Ramachandran, Rick G. Schnellmann, Darren P. Wallace +2 more

Quantitative image analysis of intracellular protein translocation in 3-dimensional tissues for pharmacodynamic studies of immunogenic cell death

Journal of Controlled Release(2023)10.1016/j.jconrel.2023.11.023

N/A

0DataRank · unranked

5 citations

Ze Lu, John A. Taylor, Jessie L.‐S. Au, Yajing Sun

Fosciclopirox clinical proof of concept in patients with nonmuscle invasive and muscle-invasive bladder cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e16557

N/A

0DataRank · unranked

2 citations

Elizabeth R. Kessler, Janet Baack Kukreja, Gerald S. Falchook, Manojkumar Bupathi, Rahul Atul Parikh +15 more